Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02488759
Recruitment Status : Active, not recruiting
First Posted : July 2, 2015
Last Update Posted : January 20, 2022
Ono Pharmaceutical Co. Ltd
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 14, 2021
Estimated Study Completion Date : August 4, 2022
Publications automatically indexed to this study by Identifier (NCT Number):